Schering PEG-Intron/Rebetol U.S. Filing Slated For First Quarter 2001

Schering-Plough's U.S. filing for PEG-Intron (peginterferon alfa-2b) in combination with Rebetol (ribavirin) for the treatment of chronic hepatitis C is expected in the first quarter of 2001.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet